Sentences with phrase «-lcb- thalidomide»

Probably the most infamous teratogen is thalidomide, a tranquilizing, anti-nausea and sleep - inducing drug.

Although thalidomide has been the subject of hundreds of studies, we still do not know exactly how it causes its effects.

That thalidomide was not approved for sale in the United States was more of a bureaucratic fluke than anything else.

For some time, no one suspected that thalidomide was the cause of the significant increase in the incidence of phocomelia.

They stopped thalidomide, after all.

Don't wait for the too little too late DES and thalidomide style recalls, decades after the fact.

The company challenges the claim that thalidomide can cause limb defects that are confined to one side of the body, as seen in nine of the plaintiffs.

Conventional wisdom has long held that thalidomide's signature defect — a shortened, seal - like «flapper» arm, known as phocomelia — affects both sides of the body.

When asked by Nature for relevant studies, the plaintiffs» lawyers at Hagens Berman Sobol Shapiro in Seattle, Washington, pointed to work showing one - sided limb defects in chick embryos exposed to thalidomide and thalidomide analogues (C. Therapontos et al..

«A universe of thalidomide related injuries has been thereby excluded from diagnosis.»

In a new twist of a historic tragedy, 13 Americans who say they are survivors of thalidomide are suing four companies for producing and distributing the notorious drug.

The lawsuit, filed in a Philadelphia court on 25 October, asserts that before thalidomide was pulled from markets around the world, samples were doled out to more than 1,200 physicians in the United States by three companies whose legal liabilities are now the property of Sanofi - Aventis US, based in Bridgewater, New Jersey.

She notes that Smith Kline & French never manufactured or sold thalidomide and adds: «The Plaintiffs» complaint is replete with scientific inaccuracies and misstatements.»

«There are no representative, controlled studies documenting the true spectrum of thalidomide injuries,» they write in the lawsuit.

«The biggest issue facing the lawyers is persuading authorities that thalidomide gave rise to a range of other defects, including unilateral limb defects — or that it caused other damage without apparent limb defects at all.»

Holmes also notes that the relative paucity of thalidomide births in the United States means that few researchers there can speak with authority on the drug's effects.

But Kelsey's body of work goes well beyond thalidomide.

The pharmacologist felt the animal studies submitted were not a good indication of possible toxicity in humans, since animals absorb thalidomide poorly.

At the FDA, Kelsey determined that thalidomide studies were incomplete and did not support the maker's claims.

President John F. Kennedy honors FDA medical officer Frances Kelsey in 1962 for her work blocking U.S. approval of thalidomide.

Meanwhile, reports of startling birth defects in babies born to mothers who had taken thalidomide were surfacing in Germany, Australia and other countries where the drug was legal — including Kelsey's native Canada.

In July 1962, a detailed story about America's close call with thalidomide appeared on the front page of The Washington Post, under the headline «Heroine of FDA Keeps Bad Drug Off Market,» with a photo of Kelsey.

By November 1961, thalidomide was taken off the market in Germany, and other countries soon followed.

For example, in its current work, the team showed that the micro-hearts didn't develop properly if exposed to thalidomide, a drug that infamously resulted in birth defects when pregnant women took it to treat morning sickness.

Much like BMS, Celgene also made a big gamble about a decade ago when it developed a class of immune - modulating drugs that included the infamous teratogen thalidomide.

The change came about after a massive scandal surrounding the drug thalidomide, which in the 1950s was widely prescribed to pregnant women to alleviate morning sickness.

FDA medical officer Frances Oldham Kelsey averted the tragedy of thalidomide birth defects in the United States

There are no babies rendered obviously deformed, as with thalidomide.

Scathing of drugs companies and the way they often put profits before human life, he had earlier fought for the rights of victims of the drug thalidomide.

If you look at the original work on the epidemiology of thalidomide [a morning - sickness drug that turned out to cause birth defects], there were specific time points where, if the woman was exposed, the baby had a high probability of having bona fide autism.

One victory: Gilla Kaplan, now a researcher at the Public Health Institute in Newark, New Jersey, found that the drug thalidomide — banned in 1962 after it was linked to severe birth defects — could reduce inflammatory responses and might be valuable in managing HIV, tuberculosis, cancer, and autoimmune diseases such as lupus.

The ongoing repurposing of the infamous drug thalidomide may include treatment of Crohn's disease, an incurable bowel condition.

The company in - licensed thalidomide in 1992 and received FDA approval to market the drug (as Thalomid) for treating severe cutaneous manifestations of leprosy in 1998 and for treating multiple myeloma in combination with dexamethasone in 2006.

Starting in 2008, Marzia Lazzerini of the Institute for Maternal and Child Health in Trieste, Italy, and her colleagues randomly assigned 54 children with Crohn's to get daily thalidomide or a placebo.

A new study published in the March 12 issue of Science has identified one primary target of thalidomide's teratogenicity (potential to cause fetal malformations)-- a protein called cereblon.

Ito and colleagues hope the identification of cereblon as a target for thalidomide teratogenicity will lead to rapid screening for similar, safer alternatives.

But little has been reported about thalidomide's direct molecular targets.

More recently, thalidomide has made a comeback.

A safe substitute for thalidomide would be well received.

Worldwide, roughly 10,000 affected children nicknamed «thalidomide babies» were born with multiple defects, including the characteristic shortened upper limbs (a condition known as phocomelia, Greek for «seal limbs»), before the drug was discontinued in 1961 after four years on the market.

In a related report former WHO Global Leprosy Program team leader Vijaykumar Pannikar wrote, «It can not be overemphasized that any potential benefit with thalidomide must be balanced with the known toxicity and the accompanying ethical and legal constraints on its use.»

In both zebrafish and chick embryos, adding a version of cereblon that doesn't bind to thalidomide seemed to blunt the drug's effects.

Handa's team found that beads tagged with thalidomide bound to a little - known protein called cereblon, which is expressed widely in both embryonic and adult tissues.

Toxicologist Craig Harris of the University of Michigan, Ann Arbor, who has studied thalidomide's effects on gene expression, says that the new data are consistent with some theories of the drug's action, however.

Now, for the first time, researchers have found a specific protein that binds to thalidomide and may help explain its devastating effects on fetal development.

That, in turn, could finally relegate thalidomide to the history books.

But given that the protein is found in so many tissues, it's puzzling that thalidomide has such specific effects on limbs, ears, eyes, gut, and kidneys.

Most recently, he said it might lead to similar health problems as the drug thalidomide.

The prime example is thalidomide, which was outlawed in the 1960s because it caused birth defects but has now found a niche in the treatment of cancer and leprosy.

To test the potential of the system as a drug - screening tool, the researchers exposed the differentiating cells to thalidomide, a drug known to cause severe birth defects.